Blood test may predict immunotherapy success in liver cancer
NCT ID NCT07273708
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at blood samples from 20 people with advanced liver cancer who are starting immunotherapy. Researchers want to find genetic clues in immune cells that can tell if a patient will respond well to treatment. The goal is to better understand why some patients benefit and others do not.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HCC TREATED BY SYSTEMIC IMMUNOTHERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione IRCCS Policlinico San Matteo
RECRUITINGPavia, Lombardy, 27100, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immunotherapy drug durvalumab may be safe for liver cancer patients with active hepatitis b
- Immunotherapy-Targeted therapy combo shows promise for advanced liver cancer
- New drug zanzalintinib tested for advanced liver cancer
- New drug cocktail shows promise for tough liver cancer
- Promising drug cocktail targets Hard-to-Treat liver cancer
- Virus therapy takes on liver cancer in major trial